From The Economic Times · Teena Thacker · · 1m 10s
Cancer Drugs Get 30% Trade Margin Cap
Experts finalize cancer drugs list under 30% trade margin cap to save ₹2,500 crore annually.
In brief
Experts finalize cancer drugs list under 30% trade margin cap to save ₹2,500 crore annually. India's government caps trade margins on cancer drugs at 30%, potentially saving patients ₹2,500 crore yearly. Originally reported by The Economic Times.
Experts to finalize cancer drugs list
A group of experts including doctors from Tata Memorial Centre and NPPA officials will finalize cancer medicines covered under a 30% trade margin cap by Wednesday.
30% trade margin cap reduces prices
The government caps trade margins on non-scheduled anti-cancer medicines at 30%, potentially lowering maximum retail prices by up to 70%.
Annual savings of ₹2,500 crore
This move could save patients an estimated ₹2,500 crore annually through reduced prices on cancer drugs.
Market analysis shows high markups
NPPA analysis found non-scheduled anti-cancer medicines had average trade markups of 170% with some reaching up to 700%.
Trade margin rationalisation applies broadly
The trade margin rationalisation exercise covers branded and generic drugs, domestic and imported products, and both patented and non-patented medicines.
Savings expected to last
The positive list may be updated periodically based on market developments and public health considerations to maintain savings.
What it means
India's government caps trade margins on cancer drugs at 30%, potentially saving patients ₹2,500 crore yearly.
